MTAP缺失在致癌驱动非小细胞肺癌中常见,可能对PRMT5抑制剂联合靶向治疗敏感
临床前显示MTA协同PRMT5抑制剂BMS-986504在MTAP缺失模型中具活性,并与靶向治疗协同或相加。
要点
- MTAP缺失在ALK重排、RET重排和EGFR突变NSCLC中频繁出现。
- MTAP缺失通常出现在靶向治疗前,且不影响一线奥希替尼或阿来替尼的疗效。
- MTA协同PRMT5抑制剂BMS-986504在MTAP缺失驱动模型中显示活性并与靶向治疗协同。
核心结论
- MTAP缺失在致癌驱动NSCLC中常见,尤其见于ALK、RET和EGFR改变亚型,MTA协同PRMT5抑制在MTAP缺失驱动模型中显示广谱活性并可能增强靶向治疗疗效。
研究设计与样本
- 临床前在体外、离体和体内MTAP缺失模型中测试BMS-986504单药及联合靶向治疗。
主要发现
- MTAP缺失频率:ALK重排NGS 27%和33%、IHC 36%和45%;RET重排NGS 18.5%和26%、IHC 35%;EGFR突变NGS 17%和24%、IHC 24%和29%。
- CDKN2A共缺失见于98%的MTAP缺失病例,MTAP缺失通常出现在靶向治疗前。
- MTAP缺失未显著影响EGFR突变和ALK重排NSCLC一线奥希替尼或阿来替尼的缓解或总生存。
- BMS-986504在11/18 MTAP缺失模型中显示纳摩尔活性,包括5/8 EGFR驱动和5/5 ALK驱动模型,与靶向治疗协同或相加见于11/18模型。
- 在克唑替尼耐药ALK重排离体球体和奥希替尼耐药EGFR突变PDX模型中,BMS-986504联合靶向治疗显示优于单药的抗肿瘤活性。
临床怎么用
- 对ALK、RET和EGFR驱动NSCLC可考虑检测MTAP缺失以识别潜在PRMT5抑制剂联合靶向治疗获益人群。
- MTAP缺失状态不宜用于预测一线奥希替尼或阿来替尼的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homozygous loss of methylthioadenosine phosphorylase (MTAP) occurs in ∼15% of cancers and leads to partial PRMT5 inhibition, creating a selective vulnerability to PRMT5 inhibitors. The frequency and therapeutic relevance of MTAP loss in oncogene-driven non-small-cell lung cancers (NSCLCs) remain underexplored. METHODS: MTAP status was assessed by next-generation sequencing (NGS) or immunohistochemistry (IHC) in >13 000 NSCLC samples in four cohorts. Prevalence was assessed across oncogenic drivers and temporal dynamics in pre- and post-treatment biopsies. Clinical outcomes were analyzed in EGFR- and ALK-rearranged NSCLC treated with first-line osimertinib and alectinib, respectively. The methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor BMS-986504 was tested alone and in combination with targeted therapies (TT) in MTAP-deleted models in vitro, ex vivo, and in vivo. RESULTS: MTAP loss was frequent in ALK-rearranged (27% and 33% by NGS; 36% and 45% IHC), RET-rearranged (18.5% and 26% by NGS; 35% by IHC), and EGFR-mutant NSCLC (17% and 24% by NGS; 24% and 29% by IHC), with CDKN2A co-deletion in 98% of cases. MTAP loss was typically present before TT. MTAP loss did not significantly impact response or overall survival with first-line osimertinib or alectinib in EGFR-mutant and ALK-rearranged NSCLC, respectively. In preclinical studies, BMS-986504 showed nanomolar activity in 11/18 MTAP-deleted models, including 5/8 EGFR- and 5/5 ALK-driven models, regardless of TT sensitivity. Synergistic or additive effects with TT were observed in 11/18 models. In ex vivo ALK-rearranged spheroids resistant to crizotinib, the combination of BMS-986504 and alectinib improved antitumor activity over monotherapy. In an osimertinib-resistant, EGFR-mutant patient-derived xenograft model, BMS-986504 with or without osimertinib controlled tumor growth, without weight loss. CONCLUSIONS: MTAP loss is frequent in oncogene-driven NSCLC, particularly in ALK-, RET-, and EGFR-altered subtypes. MTA-cooperative PRMT5 inhibition demonstrates broad activity in MTAP-deleted, oncogene-driven models and, and may enhance targeted therapy efficacy in selected settings.
引用
- Aldea M, Lenahan SM, Locquet MA, et al. MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies. Ann Oncol. 2026. PMID: 41833902. doi:10.1016/j.annonc.2026.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。